126 related articles for article (PubMed ID: 25294870)
1. Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine.
Chang HS; Won ES; Lee HY; Ham BJ; Kim YG; Lee MS
J Psychopharmacol; 2015 May; 29(5):615-22. PubMed ID: 25294870
[TBL] [Abstract][Full Text] [Related]
2. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
Chang HS; Won E; Lee HY; Ham BJ; Lee MS
Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202
[TBL] [Abstract][Full Text] [Related]
3. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
[TBL] [Abstract][Full Text] [Related]
4. Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.
Lee HY; Kang RH; Paik JW; Jeong YJ; Chang HS; Han SW; Lee MS
Brain Res; 2009 Mar; 1262():1-6. PubMed ID: 19401164
[TBL] [Abstract][Full Text] [Related]
5. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder.
Chang HS; Lee HY; Cha JH; Won ES; Ham BJ; Kim B; Lee MS
J Clin Psychopharmacol; 2014 Aug; 34(4):446-54. PubMed ID: 24911443
[TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression.
Kang RH; Chang HS; Wong ML; Choi MJ; Park JY; Lee HY; Jung IK; Joe SH; Kim L; Kim SH; Kim YK; Han CS; Ham BJ; Lee HJ; Ko YH; Lee MS; Lee MS
J Psychopharmacol; 2010 Dec; 24(12):1755-63. PubMed ID: 19493959
[TBL] [Abstract][Full Text] [Related]
7. The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events.
Chang HS; Won ES; Lee HY; Ham BJ; Kim YG; Lee MS
J Neural Transm (Vienna); 2015 Jan; 122(1):59-68. PubMed ID: 25448875
[TBL] [Abstract][Full Text] [Related]
8. MAOA gene polymorphisms and response to mirtazapine in major depression.
Tzeng DS; Chien CC; Lung FW; Yang CY
Hum Psychopharmacol; 2009 Jun; 24(4):293-300. PubMed ID: 19382113
[TBL] [Abstract][Full Text] [Related]
9. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression.
Kang RH; Hahn SW; Choi MJ; Lee MS
Neuropsychobiology; 2007; 56(1):1-5. PubMed ID: 17943025
[TBL] [Abstract][Full Text] [Related]
10. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
12. Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine.
Funaki K; Nakajima S; Suzuki T; Mimura M; Uchida H
J Clin Pharmacol; 2016 Sep; 56(9):1111-9. PubMed ID: 26813241
[TBL] [Abstract][Full Text] [Related]
13. Comments on "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder".
Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):597-8. PubMed ID: 17919799
[No Abstract] [Full Text] [Related]
14. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.
Jaquenoud Sirot E; Harenberg S; Vandel P; Lima CA; Perrenoud P; Kemmerling K; Zullino DF; Hilleret H; Crettol S; Jonzier-Perey M; Golay KP; Brocard M; Eap CB; Baumann P
J Clin Psychopharmacol; 2012 Oct; 32(5):622-9. PubMed ID: 22926595
[TBL] [Abstract][Full Text] [Related]
15. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.
Kang RH; Choi MJ; Paik JW; Hahn SW; Lee MS
Int J Psychiatry Med; 2007; 37(3):315-29. PubMed ID: 18314859
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
17. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
Shen J; Chung SA; Kayumov L; Moller H; Hossain N; Wang X; Deb P; Sun F; Huang X; Novak M; Appleton D; Shapiro CM
Can J Psychiatry; 2006 Jan; 51(1):27-34. PubMed ID: 16491981
[TBL] [Abstract][Full Text] [Related]
18. Harm avoidance involved in mediating the association between nerve growth factor (NGF) gene polymorphisms and antidepressant efficacy in patients with major depressive disorder.
Yeh YW; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Chen TY; Shyu JF; Wan FJ; Lu RB; Huang SY
J Affect Disord; 2015 Sep; 183():187-94. PubMed ID: 26021968
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder.
Kasper S; Montgomery SA; Möller HJ; van Oers HJ; Jan Schutte A; Vrijland P; van der Meulen EA
World J Biol Psychiatry; 2010 Feb; 11(1):36-44. PubMed ID: 20146649
[TBL] [Abstract][Full Text] [Related]
20. Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers.
Sun D; Ma JZ; Payne TJ; Li MD
Mol Psychiatry; 2008 Apr; 13(4):398-406. PubMed ID: 17579607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
